期刊文献+

MicroRNA-125a-5p表达对弥漫大B细胞淋巴瘤耐药及临床预后的影响 被引量:6

Effect of miR-125a-5p expression on drug resistance and clinical prognosis of diffuse large B cell lymphoma
下载PDF
导出
摘要 目的检测micro RNA-125a-5p(mi R-125a-5p)在弥漫性大B细胞淋巴瘤(DLBCL)组织中的表达情况,探讨其对肿瘤耐药及预后的影响。方法收集DLBCL石蜡标本及其临床病理资料并随访;采用实时荧光定量聚合酶链反应(q RT-PCR)检测组织中mi R-125a-5p的m RNA相对表达量;用免疫组织化学染色检测肿瘤组织中P糖蛋白(P-gp)、细胞增殖核抗原(Ki-67)蛋白的表达;分析mi R-125a-5p与耐药蛋白Pgp表达的关系,以及该表达对DLBCL肿瘤细胞增殖和临床病理特征及预后的影响。结果 Mi R-125a-5p在DLBCL组中的表达高于对照组,差异有统计学意义(P<0.05);其表达量与患者乳酸脱氢酶(LDH)、免疫表型相关(P<0.05),与年龄、性别、原发部位、临床分期、国际预后指数(IPI)均无相关(P>0.05);mi R-125a-5p高表达组P-gp蛋白阳性率高于低表达组;Kaplan-Meier及Log-rank生存分析显示低表达mi R-125a-5p患者的总生存期(OS)及无复发生存期(RFS)均高于高表达组,COX风险比例模型分析显示Ann Arbor分期Ⅲ、Ⅳ期及mi R-125a-5p高表达均可作为DLBCL患者预后不良的因素。结论 mi R-125a-5p与DLBCL耐药蛋白P-gp表达相关,mi R-125a-5p高表达及Ann Arbor分期Ⅲ、Ⅳ提示DLBCL患者预后较差,可作为潜在的DLBCL预后预测分子。 Objective To detect the expression of miR-125a-5p in the tissue of diffuse large B cell lymphoma(DLBCL),and to explore its effect on tumor drug resistance and prognosis.Methods DLBCL paraffin specimens and their clinical data were collected,and the patients were followed up to complete the survival data.qRT-PCR was used to detect the relative expression of miR-125a-5p mRNA.Immunohistochemical staining was used for detection of P-gp and Ki67 protein expressions in the tumor tissue.The correlation between miR-125a-5p and resistant protein P-gp expression was statistically analyzed,and the influence of miR-125a-5p expression level on DLBCL cell proliferation and the prognosis was explored.Results miR-125a-5p expression was significantly higher in DLBCL than the reactive hyperplasia group(P<0.05);its expression quantity was related to LDH level and the immunophenotype of the patients,but not correlated with age,gender,primary site,clinical stage or IPI score(P>0.05).The positive expression rate of P-gp protein in the miR-125a-5p high-expression group was higher than that in the miR-125a-5p low-expression group.Kaplan-Meier and Log-rank survival analyses showed that the overall survival and recurrence-free survival of the patients with low expression of miR-125a-5p were higher than those of the high-expression group.COX risk proportion model analysis showed that Arbor stages III and IV and miR-125a-5p high expression are the independent factors of poor prognosis of the patients with DLBCL.Conclusions The expression of miR-125a-5p is associated with the expression level of drug resistant protein P-gp in DLBCL.High expression of miR-125a-5p and Arbor stages III and IV indicate poor prognosis of the patients with DLBCL.And miR-125a-5p can be used as a potential molecule for prediction of the prognosis of DLBCL.
作者 韩莹 杨文秀 濮珍红 万珑 Ying Han;Wen-xiu Yang;Zhen-hong Pu;Long Wan(Department of Pathology,Guizhou Medical University,Guiyang,Guizhou 550004,China;Department of Pathology,Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou 550004,China)
出处 《中国现代医学杂志》 CAS 2018年第19期34-40,共7页 China Journal of Modern Medicine
基金 贵州省自然科学基金(No:TJ2014-2)
关键词 大B细胞淋巴瘤 miR-125a-5p P-GP 实时荧光定量聚合酶链反应 预后 DLBCL mir-125a-5p P-gp quantitative real-time PCR prognosis
  • 相关文献

参考文献7

二级参考文献65

  • 1张海涛,王漪,余敏,刘心.K562/A02细胞株核因子-κB活性与P糖蛋白的表达[J].西安交通大学学报(医学版),2006,27(4):349-351. 被引量:2
  • 2王漪,刘心,张海涛,余敏,王晖.白血病细胞中NF-κB调控MDR1基因、P糖蛋白及逆转耐药的研究[J].中国实验血液学杂志,2007,15(5):950-954. 被引量:12
  • 3张之南,沈悌.血液病诊断及疗效标准[M].第3版.北京:科学出版社,2008.232-235.
  • 4Steven H, Elias C, Nancy LH, et al. WHO Classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues [ M ]. Lyon : IARC Press,2008:233.
  • 5Amytage JO, Weisenburger DD. New approach to classifying non-Hodgkins lymphoma:clinical features of the major his- tologic subtypes. Non-Hodgkins lymphoma Classification Project [J]. J Cli Oncol, 1998,16 (8) :2780.
  • 6Moiler MB, Kania PW, Ino Y, et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma:prognos- tic significance of E2F-1 and pl6INK4A [ J ]. Leukemia, 2000,14(5) :898.
  • 7Espinosa I, Briones J, Bordes R, et al. Activation of the NF- KB signalling pathway in diffuse large B-cell lymphoma: clinical implications [ J 1. Histopathology ,2008,53 (4) :441.
  • 8Masahiko Ohsawa, Yoshihiro Ikura, Hiroko Fukushima, et a- 1. Immunohistochemical Expression of Muhidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lympho- ma[J]. Oncology,2005,68(4-6) :422.
  • 9Rovesdi I, Reielel R, Novins JR. Identification of a cellular transcription factor involved in E1A transactivation [ J ]. Cell, 1986,45 (2) :219.
  • 10Suh DS, Yoon MS, Choi KU, et al. Significance of E2F-1 overexpression in epithelial ovarian cancer[ J]. Int J Gyne-col Cancer, 2008,18 (3) :492.

共引文献34

同被引文献42

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部